Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model

International Journal of Pharmaceutics

Volumn 441, Issue 1-2, 2013, Pages 499-506

  Kratz, Felix ^a   Azab, Samar ^a,b   Zeisig, Reiner ^c   Fichtner, Iduna ^c   Warnecke, André ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b Ain Shams University   (Egypt)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

(6 Maleimidocaproyl)hydrazone of doxorubicin; Combination therapy; DOXO EMCH; Doxorubicin; Human serum albumin; INNO 206; Pancreatic cancer; Prodrugs

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACID; ALBUMIN; ALDOXORUBICIN; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CANCER REGRESSION; CELL VIABILITY; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOTOXICITY TEST; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL CULTURE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; HYDRAZONES; INJECTIONS, INTRAVENOUS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PRODRUGS; REMISSION INDUCTION; SERUM ALBUMIN; TIME FACTORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872784581     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.11.003     Document Type: Article

References (37)

1. P. Albertsson, B. Lennernas, and K. Norrby Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting APMIS 111 2003 995 1003
2. W.S. Ammons, J.W. Wang, Z. Yang, G.F. Tidmarsh, and R.M. Hoffman A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo Neoplasia 9 2007 625 633
3. R. Baurain, D. Deprez-De Campeneere, and A. Trouet Determination of daunorubicin, doxorubicin and their fluorescent metabolites by high-pressure liquid chromatography: plasma levels in DBA2 mice Cancer Chemother. Pharmacol. 2 1979 11 14
4. U. Beyer, B. Rothern-Rutishauser, C. Unger, H. Wunderli-Allenspach, and F. Kratz Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy Pharm. Res. 18 2001 29 38
5. H.A. Burris III, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, M.C. Cripps, R.K. Portenoy, A.M. Storniolo, P. Tarassoff, R. Nelson, F.A. Dorr, C.D. Stephens, and D.D. Von Hoff Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15 1997 2403 2413
6. Q. Chang, E. Chen, and D.W. Hedley Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models Cancer Biol. Ther. 8 2009 1893 1901
7. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Parasitol. Res. 58 2006 621 681
8. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
9. D. Fukumura, D.G. Duda, L.L. Munn, and R.K. Jain Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models Microcirculation 17 2010 206 225
10. R. Graeser, N. Esser, H. Unger, I. Fichtner, A. Zhu, C. Unger, and F. Kratz INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model Investig. New Drugs 28 2009 14 19
11. V. Heinemann, D. Quietzsch, F. Gieseler, M. Gonnermann, H. Schonekas, A. Rost, H. Neuhaus, C. Haag, M. Clemens, B. Heinrich, U. Vehling-Kaiser, M. Fuchs, D. Fleckenstein, W. Gesierich, D. Uthgenannt, H. Einsele, A. Holstege, A. Hinke, A. Schalhorn, and R. Wilkowski Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J. Clin. Oncol. 24 2006 3946 3952
12. F. Kratz DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials Expert Opin. Investig. Drugs 16 2007 855 866
13. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
14. F. Kratz, and U. Beyer Serum proteins as drug carriers of anticancer agents: a review Drug Deliv. 5 1998 281 299
15. F. Kratz, and B. Elsadek Clinical impact of serum proteins on drug delivery J. Control. Release 161 2012 429 445
16. F. Kratz, I. Fichtner, and R. Graeser Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model Investig. New Drugs 30 2012 1743 1749
17. F. Kratz, T. Roth, I. Fichtner, P. Schumacher, H.H. Fiebig, and C. Unger In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model J. Drug Target. 8 2000 305 318
18. F. Kratz, and A. Warnecke Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems J. Control. Release 164 2012 221 235
19. F. Kratz, A. Warnecke, K. Scheuermann, C. Stockmar, J. Schwab, P. Lazar, P. Drückes, N. Esser, J. Drevs, D. Rognan, C. Bissantz, C. Hinderling, G. Folkers, I. Fichtner, and C. Unger Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound J. Med. Chem. 45 2002 5523 5533
20. S.H. Lee, J.K. Ryu, K.Y. Lee, S.M. Woo, J.K. Park, J.W. Yoo, Y.T. Kim, and Y.B. Yoon Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer Cancer Lett. 259 2008 39 49
21. B. Lennernas, P. Albertsson, H. Lennernas, and K. Norrby Chemotherapy and antiangiogenesis - drug-specific, dose-related effects Acta Oncol. 42 2003 294 303
22. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
23. S. Nakahira, S. Nakamori, M. Tsujie, S. Takeda, K. Sugimoto, Y. Takahashi, J. Okami, S. Marubashi, A. Miyamoto, Y. Takeda, H. Nagano, K. Dono, K. Umeshita, M. Sakon, and M. Monden Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts Anticancer Res. 28 2008 179 186
24. J.P. Neoptolemos, D.D. Stocken, C. Bassi, P. Ghaneh, D. Cunningham, D. Goldstein, R. Padbury, M.J. Moore, S. Gallinger, C. Mariette, M.N. Wente, J.R. Izbicki, H. Friess, M.M. Lerch, C. Dervenis, A. Olah, G. Butturini, R. Doi, P.A. Lind, D. Smith, J.W. Valle, D.H. Palmer, J.A. Buckels, J. Thompson, C.J. McKay, C.L. Rawcliffe, and M.W. Buchler Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 304 2010 1073 1081
25. E. Sanchez, M. Li, C. Wang, C.M. Nichols, J. Li, H. Chen, and J.R. Berenson Anti-myeloma effects of the novel anthracycline derivative INNO-206 Clin. Cancer Res. 18 2010 3856 3867
26. R.M. Schultz, R.L. Merriman, J.E. Toth, J.E. Zimmermann, L.W. Hertel, S.L. Andis, D.E. Dudley, P.G. Rutherford, L.R. Tanzer, and G.B. Grindey Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts Oncol. Res. 5 1993 223 228
27. S.B. Sobottka, and M.R. Berger Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties Cancer Chemother. Pharmacol. 30 1992 385 393
28. H.S. Song, Y.R. Do, H.M. Chang, M.H. Ryu, K.H. Lee, Y.H. Kim, D.S. Hong, J.Y. Cho, K.E. Lee, and S.Y. Kim A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer Cancer Chemother. Pharmacol. 62 2008 763 768
29. I.F. Tannock, and D. Rotin Acid pH in tumors and its potential for therapeutic exploitation Cancer Res. 49 1989 4373 4384
30. R.T. Tong, Y. Boucher, S.V. Kozin, F. Winkler, D.J. Hicklin, and R.K. Jain Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res. 64 2004 3731 3736
31. P.A. Trail, D. Willner, S.J. Lasch, A.J. Henderson, R.S. Greenfield, D. King, M.E. Zoeckler, and G.R. Braslawsky Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models Cancer Res. 52 1992 5693 5700
32. M. Tsujie, S. Nakamori, E. Tanaka, H. Nagano, K. Umeshita, K. Dono, M. Sakon, T. Inoue, and M. Monden Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer Jpn. J. Clin. Oncol. 36 2006 504 510
33. C. Unger, B. Haring, M. Medinger, J. Drevs, S. Steinbild, F. Kratz, and K. Mross Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin Clin. Cancer Res. 13 2007 4858 4866
34. A. Vincent, J. Herman, R. Schulick, R.H. Hruban, and M. Goggins Pancreatic cancer Lancet 378 2011 607 620
35. J. Yoshizawa, A. Takizawa, O. Takeuchi, O. Hiraku, K. Sasaki, Y. Morimoto, K. Atsuda, G. Inoue, Y. Suzuki, F. Asanuma, and Y. Yamada Experimental study of combination therapy with S-1 against pancreatic cancer Cancer Chemother. Pharmacol. 64 2009 1211 1219
36. I.S. Zagon, J.R. Jaglowski, M.F. Verderame, J.P. Smith, A.E. Leure-Dupree, and P.J. McLaughlin Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma Cancer Chemother. Pharmacol. 56 2005 510 520
37. C.P. Zhu, J. Shi, Y.X. Chen, W.F. Xie, and Y. Lin Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis Radiother. Oncol. 99 2011 108 113